Transaction · 0001493152-26-049370

Trieu Vuong

Trieu Vuong, CHAIR, reported an open-market or private purchase at Oncotelic Therapeutics, Inc. involving 1044990.000000 shares. Reported holdings after the transaction were 95481309.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market buySEC transaction code PCHAIR
OTLCOncotelic Therapeutics, Inc.
Trade date
Oct 29, 2026
Filing date
Oct 30, 2026
View on SEC Insider profile
Disclosed valueUnknownShares × reported price
Shares traded1.04MPrice unknown
Holdings after95.4MDirect
% of reported position traded1.11%This security and ownership context
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 94,436,319 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

OTLC price since this filing

Daily closing prices, with the filing date and available return windows
OTLC · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Buy
Code P
Identifier
0001493152-26-049370
Common Stock
Transaction date
Oct 29, 2026
Filed Oct 30, 2026, 01:00 PM · 1d delay
Shares
1,044,990 sh
Price unknown
Estimated value
—
Computed from shares × price
Holdings after
95,481,309 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Director Buy Direct Ownership 10% Owner Buy
Filing-only score

+20 points

Compact filing score computed from stored Form 4 facts. Version v1.

Positive filing signal

This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.

How this score is calculated
  • open_market_purchase+12 points

    transaction_code = P

    Code P is a discretionary open-market purchase.
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • director_buy+6 points

    is_director = true

    Director open-market purchase.
  • timely_filing+4 points

    reporting_delay_days = 1

    Filing reported within two business days of the transaction.
  • missing_price-8 points

    price_cents is null

    Missing price reduces confidence in value-based signals.
Missing facts
  • price_cents
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CHAIRMAN AND CEO

Officer YesDirector Yes10% YesOther No
Footnotes & amended
  1. F1

    On October 29, 2026, Dr. Vuong Trieu purchased 1,044,990 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.017.

  2. F2

    On October 28, 2026, Dr. Vuong Trieu purchased 312,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0185.

Original filing · 0001493152-26-049370
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

OTLC